The notion that RG may have a dual protective action related to its known activity as a Cx43 activator and to a novel Cx43-independent inhibiting action on NF-κB activation makes RG an attractive candidate for mono- or combination therapy in diabetes. This evidence concerns the gene GJA1 and diabetes mellitus.